Yifeng Pharmacy Chain (603939) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 reached ¥5.56 billion, up 1.97% year-over-year; year-to-date revenue was ¥17.29 billion, up 0.39% year-over-year.

• Net profit attributable to shareholders for Q3 was ¥344.51 million, up 10.14% year-over-year; year-to-date net profit was ¥1.22 billion, up 10.27% year-over-year.

• 137 new stores opened and 440 closed in the first nine months; total store count at period end was 14,666, a net decrease of 18 stores from last year.

Financial highlights

• Operating profit for the first nine months was ¥1.58 billion, up from ¥1.40 billion year-over-year.

• Gross margin improved as cost of sales grew slower than revenue; gross profit for the period was ¥6.98 billion.

• Basic EPS for Q3 was ¥0.28, up 7.69% year-over-year; year-to-date basic EPS was ¥1.01, up 9.78%.

• Net cash flow from operating activities for the first nine months was ¥2.27 billion, down 32.16% year-over-year due to increased cash outflows from maturing bank acceptance bills.

Outlook and guidance

• Management highlighted ongoing store network optimization and continued focus on profitability.